Clinical Trial Update: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 update on LY4066434, a pan-KRAS inhibitor, in KRAS-mutant solid tumors, including pancreatic ductal adenocarcinoma and non-small cell lung cancer, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• LY4066434

Snippet

Sponsor: Eli Lilly and Company | Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING